Three-year clinical outcome using the Contura multilumen balloon breast brachytherapy catheter to deliver accelerated partial breast irradiation (APBI): Improving radiation standards for the optimal application of APBI

详细信息	查看全文 | 推荐本文 |

• 作者：Philip Z. Israel¹ ; ^{pzisrael@aol.com} ; Angela Robbins¹ ; Paulomi Shroff¹ ; Sheree Brown² ; Mark McLaughlin² ; Keith Pope²
• 关键词：Balloon brachytherapy ; Partial breast irradiation ; Breast cancer ; Contura MLB ; MammoSite
• 刊名：Brachytherapy
• 出版年：2012
• 期刊代码：278_15384721
• 类别：med
• 出版时间：July-August, 2012
• 卷：11
• 期：4
• 页码：316-321
• 文件大小：108 K

摘要

Purpose

We reviewed our institution鈥檚 3-year clinical experience in treating patients with the Contura multilumen balloon (SenoRx, Inc., Aliso Viejo, CA) breast brachytherapy catheter to deliver accelerated partial breast irradiation (APBI).

Methods and Materials

Forty-six patients treated with breast-conserving therapy received adjuvant radiation using the Contura catheter (34 Gy in 3.4 Gy fractions). Fourteen patients had Stage 0, 24 had Stage I, and 8 had Stage II breast cancer. Median follow-up was 36聽months (range, 1-44 months).

Results

Only one local recurrence developed (2%). The rate of persistent seroma formation at latest reported follow-up was 4.3%(2 patients) and the incidence of any clinically detectable telengiectasias was 2.2%. No major toxicities (0%Grade III) have occurred. The median skin dose (%聽of the prescribed dose) was 99.7. The median dose to 95%of the planning target volume for evaluation was 98.8%. The percentage of patients with excellent/good cosmetic results at 24聽(n = 23) and 36 (n = 22) months was 100%and 97%, respectively.

Conclusion

Adjuvant APBI using the Contura multilumen balloon catheter exhibited similar locoregional control, cosmesis, and toxicities to other forms of APBI with similar lengths of follow-up. In addition, improved radiation standards for the delivery of APBI were demonstrated.